Financial Performance - The company's revenue for Q1 2024 was CNY 2,670,740,738.16, a decrease of 1.95% compared to CNY 2,723,970,949.97 in the same period last year[8] - Net profit attributable to shareholders was CNY 230,557,834.70, down 33.80% from CNY 348,255,328.87 year-on-year[8] - The adjusted net profit attributable to shareholders was CNY 338,816,299.13, reflecting a decrease of 22.70% compared to CNY 438,339,247.42 in the previous year[8] - Operating profit decreased to CNY 268,414,806.18, down 37.8% from CNY 431,571,732.74 in the previous period[43] - Net profit for the current period was CNY 215,919,833.12, a decline of 38.2% compared to CNY 350,146,873.58 in the previous period[44] - Basic earnings per share decreased by 33.94% to ¥0.1300, driven by the reduction in net profit attributable to shareholders[16] - Diluted earnings per share fell by 34.01% to ¥0.1298, also reflecting the decrease in net profit attributable to shareholders[18] - Basic earnings per share for the current period was CNY 0.1300, down from CNY 0.1968 in the previous period[46] - The company reported a net profit of RMB 215,920,000 for the current period, down 38.3% from RMB 350,148,000 in the previous year[53] - The company's basic earnings per share for the current period was RMB 0.1300, down from RMB 0.1968 in the previous year[53] Cash Flow and Assets - Cash flow from operating activities increased by 40.65% to CNY 745,630,586.78, up from CNY 530,139,954.34 in the same period last year[8] - Net cash flow from operating activities increased by 40.65% to ¥745,630,586.78, mainly due to an increase in sales collections[16] - Cash and cash equivalents decreased from CNY 5,918,915,276.72 to CNY 4,633,337,568.45, representing a decrease of about 21.7%[36] - The total current assets decreased from CNY 10,874,413,206.01 to CNY 9,448,379,249.76, a decline of approximately 13.1%[36] - The total assets at the end of the reporting period were CNY 25,243,967,050.83, a decrease of 4.66% from CNY 26,476,712,835.60 at the end of the previous year[8] - The total assets decreased from CNY 26,476,712,835.60 to CNY 25,243,967,050.83, a decline of about 4.7%[37] - The total assets less current liabilities amounted to RMB 21,487,864,000, a decrease from RMB 22,822,237,000 at the end of the previous period[54] Liabilities and Equity - Total liabilities decreased to CNY 11,886,956,291.91 from CNY 13,238,666,497.83, reflecting a reduction of 10.2%[41] - Non-current liabilities totaled CNY 8,130,853,112.80, down 15.2% from CNY 9,584,190,645.48[41] - The total equity attributable to the parent company increased to CNY 12,687,089,142.67 from CNY 12,556,797,361.42, a rise of 1.04%[41] - The total equity attributable to the owners of the parent company was RMB 12,687,089,000, up from RMB 12,556,797,000, indicating an increase of 1.0%[55] Operational Highlights - The company signed new orders that increased by over 20% compared to the same period last year, indicating a recovery in customer inquiries and visits[11] - The gross profit margin for laboratory services was 44.14%, slightly down from 44.48% in the previous year[11] - The gross profit margin for clinical research services improved to 9.32%, up from 14.02% year-on-year[11] - Total operating costs increased to CNY 2,439,362,705.75, up 3.69% from CNY 2,352,273,096.85 in the previous period[43] Research and Development - Research and development expenses increased to CNY 93,605,963.99, up 22% from CNY 76,838,901.31 in the previous period[43] - Research and development expenses increased to RMB 93,606,000, compared to RMB 76,839,000 in the same period last year, reflecting a growth of 22%[53] Other Financial Metrics - The company reported a net profit from non-operating income of CNY 43,209,069.08 for the period[14] - Investment income surged by 177.35% to ¥46,569,164.93, attributed to the repurchase of certain convertible bonds during the reporting period[20] - Other comprehensive income decreased significantly by 1,136.05% to -¥59,702,067.74, mainly due to changes in cash flow hedging reserves[20] - The company reported a foreign exchange-related gain of RMB 25,063,000 in Q1 2024, compared to a loss of RMB 804,000 in the same period last year[58] - The company incurred a one-time loss of RMB 44,016,000 due to the closure of Kanglong Chemical (Shanghai) New Drug Technology Co., Ltd.[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 85,011[24] - The number of shares held by the top 10 unrestricted shareholders includes HKSCC NOMINEES LIMITED with 301,502,043 shares[26] - The company plans to release restricted shares for certain executives, with a total of 6,986,213 shares being released this period[32] - The company has ongoing stock incentive plans for 2021 and 2022, with announcements regarding vesting results expected in January 2024[34]
康龙化成(03759) - 2024 Q1 - 季度业绩